Skip to Main Content

Browse issues

Volume 47, Issue 4, 1 April 2022

ISSUE INFORMATION

Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 649–650, https://doi.org/10.1111/ced.14736

REVIEW ARTICLES

Y. Liu and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 651–657, https://doi.org/10.1111/ced.14995

Malignant acanthosis nigricans has similar pathological manifestations with other diseases that have extensive oral papillary hyperplasia. However, this can make it difficult to distinguish between the other diseases based on lesions alone. To aid in the early detection of underlying malignant diseases, we summarize the clinical features of these diseases, and discuss the management of malignant acanthosis nigricans.

X. L. Tan and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 658–666, https://doi.org/10.1111/ced.14976
K. Hussain and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 667–674, https://doi.org/10.1111/ced.15019

A review summarizing the role of thalidomide for dermatologists. The review provides case examples, explains the licensed and unlicensed doses of the medication for various conditions and the adverse effects to be aware of. Summary tables are also created for clinicians to glance through the salient points of the review.

ORIGINAL ARTICLES

R. Stalder and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 675–683, https://doi.org/10.1111/ced.14988
W. T. N. Hunt and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 684–691, https://doi.org/10.1111/ced.15012

Using six readability instruments, this study assessed the readability of the British Association of Dermatologists’ (BAD) patient information leaflets (PILs). The readability measures ascertained that most PILs provided by the BAD are written at a level that may not be comprehensible to a proportion of patients. We compare these findings to the literature and highlight methods for the BAD Clinical Standards Unit to improve readability for future PILs.

Y.‐H. Wu and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 692–699, https://doi.org/10.1111/ced.15010

This systematic review and meta‐analysis demonstrates that patients with vitiligo do not have a significantly increased risk of skin cancer after ultraviolet phototherapy compared with those not receiving phototherapy.

E. I. Ababneh and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 700–708, https://doi.org/10.1111/ced.15009

Nonuraemic calciphylaxis is more common than previously reported, and was primarily seen in obese postmenopausal women. Undiagnosed primary hyperparathyroidism might be an overlooked risk factor and lupus anticoagulant was commonly present in nonuraemic and uraemic calciphylaxis patients. Histopathologically, extravascular calcification is more common in patients with nonuraemic calciphylaxis.

L. Hefez and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 709–716, https://doi.org/10.1111/ced.15039

During isotretinoin treatment, special attention is required to detect any symptom or change in mental health. Our pilot, national, multicentre, prospective study assessed the acceptability of the Adolescent Depression Rating Scale for monitoring symptoms among adolescents before and during isotretinoin treatment in dermatology real‐life practice.

S. J. Robertson and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 717–723, https://doi.org/10.1111/ced.15029

We present otological complications in the rare inversa subtype of recessive dystrophic epidermolysis bullosa, as well as experience with bone anchored hearing aids in this subgroup.

A. Ningombam and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 724–729, https://doi.org/10.1111/ced.15032

Recent evidence has suggested that oral antihistamines could have a beneficial role in atopic dermatitis (AD) due to their anti‐inflammatory action. The observations in the present study indicate that fexofenadine treatment can lead to significant lowering of levels of serum interleukin‐31, the major cytokine mediating itch, in patients with AD.

CONCISE REPORTS

A. Mohta and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 730–734, https://doi.org/10.1111/ced.14968
J. Triwatcharikorn and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 735–738, https://doi.org/10.1111/ced.14962
C. A. Rauen and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 739–742, https://doi.org/10.1111/ced.14999

Two male patients living in conditions of vulnerability were affected by myiasis. Both were treated by ivermectin, debridement, antibiotic therapy and preventive care guidance. There is a need to implement care for prevention and attention to the general health of those patients affected by oral myiasis, as the lack of this is often a clear sign of neglect.

C. Divyalakshmi and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 743–747, https://doi.org/10.1111/ced.15016

Sequential chemical peel therapy with salicylic acid and glycolic acid can be an effectual and prudent treatment option for difficult to treat cases of cutaneous amyloidosis.

LETTER TO THE EDITOR

Correspondence

L. Joos and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 748–750, https://doi.org/10.1111/ced.15005
A. Mohammed and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 750–751, https://doi.org/10.1111/ced.15004
A. Amir Ali and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 751–753, https://doi.org/10.1111/ced.15022
A. Moussa and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 753–755, https://doi.org/10.1111/ced.15051
M. Attard and D. O’Kane
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 755–757, https://doi.org/10.1111/ced.15028
J. Maghfour and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 757–759, https://doi.org/10.1111/ced.15026
L. Killion and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 759–763, https://doi.org/10.1111/ced.15030
M. de Brito and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 763–764, https://doi.org/10.1111/ced.15031
L.‐W. Zhang and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 764–765, https://doi.org/10.1111/ced.15036
E. Barbosa and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 765–767, https://doi.org/10.1111/ced.15043
M. K. Y. Chen and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 767–768, https://doi.org/10.1111/ced.15034
Y. Mizuno and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 768–769, https://doi.org/10.1111/ced.15042
F. R. Ali and J. T. Lear
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 769–770, https://doi.org/10.1111/ced.15047
Nicholas Manuelpillai and Emma Veysey
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 770–773, https://doi.org/10.1111/ced.15048
Roberto Maglie and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 773–775, https://doi.org/10.1111/ced.15055
Sakurako Arai and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 775–778, https://doi.org/10.1111/ced.15065
Arcadi Altemir and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 778–780, https://doi.org/10.1111/ced.15060
Khawar Hussain and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Page 778, https://doi.org/10.1111/ced.15062
Pallavi Hegde and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 780–782, https://doi.org/10.1111/ced.15069
Wei‐Cheng Fang and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 782–783, https://doi.org/10.1111/ced.15070
Antonio Carriero and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 783–785, https://doi.org/10.1111/ced.15061
Xia‐er‐ba‐ti Ha‐bu‐lie‐ti and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 785–787, https://doi.org/10.1111/ced.15066
Alexander Kreuter and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 787–788, https://doi.org/10.1111/ced.15044

Patient viewpoint

Deborah Cox and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 789–790, https://doi.org/10.1111/ced.15064

CONTINUING PROFESSIONAL DEVELOPMENT

Clinicopathological cases

A. J. Seine and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 791–794, https://doi.org/10.1111/ced.15050
S. Cameron and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 795–798, https://doi.org/10.1111/ced.15040
Mia Steyn and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 799–801, https://doi.org/10.1111/ced.15045
Áine Kelly and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 802–805, https://doi.org/10.1111/ced.15025

A memorable patients

Arcadi Altemir and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 806–808, https://doi.org/10.1111/ced.15056
Leila Nemazee and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 809–811, https://doi.org/10.1111/ced.15033

Genetic report

S. V. Braz and others
Clinical and Experimental Dermatology, Volume 47, Issue 4, 1 April 2022, Pages 812–815, https://doi.org/10.1111/ced.15046
Close
This Feature Is Available To Subscribers Only

Sign In or Create an Account

Close

This PDF is available to Subscribers Only

View Article Abstract & Purchase Options

For full access to this pdf, sign in to an existing account, or purchase an annual subscription.

Close